Clinical Trial Update: Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant therapy with proxalutamide plus androgen deprivation therapy for high-risk prostate cancer; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• proxalutamide (proxalutamide)

Snippet

Sponsor: Hongqian Guo | Conditions: Neoadjuvant Therapy \High Risk Prostate Cancer | Phase 2 | Status: UNKNOWN